Patents by Inventor Eun-Yi CHO

Eun-Yi CHO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240300902
    Abstract: The present invention relates to a series of novel benzoimidazole derivatives and their use.
    Type: Application
    Filed: November 18, 2021
    Publication date: September 12, 2024
    Applicant: MD BIOLAB CO., LTD.
    Inventors: Sang Woo KIM, Hyun Cheol CHUNG, Eun Yi CHO, Ye Rin JO, Hyeon Joo KIM, Byeong Hak MOON, Yong Chul KIM, Jin Su BAE, Ga Ram KIM, Soo Youl KIM
  • Publication number: 20230390320
    Abstract: The present disclosure relates to a cancer-specific trans-splicing ribozyme and a use thereof. The trans-splicing ribozyme does not act on normal tissues but is specifically expressed in cancer tissues, and thus the safety thereof is high and the expression efficiency thereof is excellent at the post-transcription level, and one or more target genes are connected to the 3? exon of the ribozyme so that a cancer therapeutic gene and an immune checkpoint inhibitor are expressed together when applied in vivo, and thus the present disclosure can be effectively used in cancer treatment.
    Type: Application
    Filed: January 21, 2022
    Publication date: December 7, 2023
    Applicant: Rznomics Inc.
    Inventors: Seong-Wook LEE, Eun Yi CHO, Tae Young KIM, Hye Rim PARK
  • Patent number: 11827696
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: November 28, 2023
    Assignee: Sung Kyun Biotech Co., Ltd.
    Inventors: Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
  • Patent number: 11746146
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: September 5, 2023
    Assignee: SUNG KYUN BIOTECH CO., LTD.
    Inventors: Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
  • Patent number: 11732035
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: August 22, 2023
    Assignee: Sung Kyun Biotech Co., Ltd.
    Inventors: Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
  • Patent number: 11498945
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: November 15, 2022
    Assignee: Sung Kyun Biotech Co., Ltd.
    Inventors: Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
  • Publication number: 20220106368
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: SUNG KYUN BIOTECH CO., LTD.
    Inventors: Kyeong-Nam YU, Eun-Yi CHO, Seung-Hee CHANG, Seon-Hee KIM, Hyun-Suk KIM, Ki-Moon PARK
  • Publication number: 20220106369
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: SUNG KYUN BIOTECH CO., LTD.
    Inventors: Kyeong-Nam YU, Eun-Yi CHO, Seung-Hee CHANG, Seon-Hee KIM, Hyun-Suk KIM, Ki-Moon PARK
  • Patent number: 11078487
    Abstract: A cancer-specific trans-splicing ribozyme and a use thereof are disclosed. The trans-splicing ribozyme does not act on normal tissue, but is specifically expressed in cancer tissue. Therefore, it is very safe and has excellent expression efficiency at the post-transcription level, and thus can be effectively used in treatment of cancer.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: August 3, 2021
    Assignees: Rznomics Inc., Dong-A University Research Foundation for Industry Academy Cooperation, Industry-Academic Cooperation Foundation, Dankook University
    Inventors: Seong-Wook Lee, Chang Ho Lee, Seung Ryul I Han, Ji Hyun Kim, Eun Yi Cho, Jin Sook Jeong, Mi Ha Ju
  • Publication number: 20200270612
    Abstract: A cancer-specific trans-splicing ribozyme and a use thereof are disclosed. The trans-splicing ribozyme does not act on normal tissue, but is specifically expressed in cancer tissue. Therefore, it is very safe and has excellent expression efficiency at the post-transcription level, and thus can be effectively used in treatment of cancer.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 27, 2020
    Applicants: Rznomics Inc., Dong-A University Research Foundation for Industry Academy Cooperation, Industry-Academic Cooperation Foundation, Dankook University
    Inventors: Seong-Wook Lee, Chang Ho Lee, Seung Ryul I Han, Ji Hyun Kim, Eun Yi Cho, Jin Sook Jeong, Mi Ha Ju
  • Publication number: 20200010518
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Application
    Filed: November 28, 2017
    Publication date: January 9, 2020
    Applicant: SUNG KYUN BIOTECH CO., LTD.
    Inventors: Kyeong-Nam YU, Eun-Yi CHO, Seung-Hee CHANG, Seon-Hee KIM, Hyun-Suk KIM, Ki-Moon PARK